272 related articles for article (PubMed ID: 29318382)
1. MiR-29 silencing modulates the expression of target genes related to proliferation, apoptosis and methylation in Burkitt lymphoma cells.
Mazzoccoli L; Robaina MC; Apa AG; Bonamino M; Pinto LW; Queiroga E; Bacchi CE; Klumb CE
J Cancer Res Clin Oncol; 2018 Mar; 144(3):483-497. PubMed ID: 29318382
[TBL] [Abstract][Full Text] [Related]
2. miR‑29 promoter and enhancer methylation identified by pyrosequencing in Burkitt lymhoma cells: Interplay between MYC and miR‑29 regulation.
Mazzoccoli L; Robaina MC; Bacchi CE; Soares Lima SC; Klumb CE
Oncol Rep; 2019 Aug; 42(2):775-784. PubMed ID: 31173259
[TBL] [Abstract][Full Text] [Related]
3. Deregulation of DNMT1, DNMT3B and miR-29s in Burkitt lymphoma suggests novel contribution for disease pathogenesis.
Robaina MC; Mazzoccoli L; Arruda VO; Reis FR; Apa AG; de Rezende LM; Klumb CE
Exp Mol Pathol; 2015 Apr; 98(2):200-7. PubMed ID: 25746661
[TBL] [Abstract][Full Text] [Related]
4. FAMLF is a target of miR-181b in Burkitt lymphoma.
Li JG; Ding Y; Huang YM; Chen WL; Pan LL; Li Y; Chen XL; Chen Y; Wang SY; Wu XN
Braz J Med Biol Res; 2017 May; 50(6):e5661. PubMed ID: 28492808
[TBL] [Abstract][Full Text] [Related]
5. Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.
Onnis A; De Falco G; Antonicelli G; Onorati M; Bellan C; Sherman O; Sayed S; Leoncini L
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20930934
[TBL] [Abstract][Full Text] [Related]
6. Potential roles of microRNA-29a in the molecular pathophysiology of T-cell acute lymphoblastic leukemia.
Oliveira LH; Schiavinato JL; Fráguas MS; Lucena-Araujo AR; Haddad R; Araújo AG; Dalmazzo LF; Rego EM; Covas DT; Zago MA; Panepucci RA
Cancer Sci; 2015 Oct; 106(10):1264-77. PubMed ID: 26251039
[TBL] [Abstract][Full Text] [Related]
7. Low expression of miR-150 in pediatric intestinal Burkitt lymphoma.
Wang M; Yang W; Li M; Li Y
Exp Mol Pathol; 2014 Apr; 96(2):261-6. PubMed ID: 24613688
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of DNA binding 4 functions as a tumor suppressor and is targetable by 5-aza-2'-deoxycytosine with potential therapeutic significance in Burkitt's lymphoma.
Gao XZ; Zhao WG; Wang GN; Cui MY; Zhang YR; Li WC
Mol Med Rep; 2016 Feb; 13(2):1269-74. PubMed ID: 26648013
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of tumor suppressor miR-3151 contributes to Chinese chronic lymphocytic leukemia by constitutive activation of MADD/ERK and PIK3R2/AKT signaling pathways.
Wang LQ; Wong KY; Rosèn A; Chim CS
Oncotarget; 2015 Dec; 6(42):44422-36. PubMed ID: 26517243
[TBL] [Abstract][Full Text] [Related]
10. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation.
Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L
J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929
[TBL] [Abstract][Full Text] [Related]
11. miR-17-92 cluster components analysis in Burkitt lymphoma: overexpression of miR-17 is associated with poor prognosis.
Robaina MC; Faccion RS; Mazzoccoli L; Rezende LM; Queiroga E; Bacchi CE; Thomas-Tikhonenko A; Klumb CE
Ann Hematol; 2016 May; 95(6):881-91. PubMed ID: 27044389
[TBL] [Abstract][Full Text] [Related]
12. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor prevents cell growth in Burkitt's lymphoma by regulating PI3K/Akt pathways and leads to upregulation of miR-143, miR-145, and miR-101.
Ferreira AC; Robaina MC; Rezende LM; Severino P; Klumb CE
Ann Hematol; 2014 Jun; 93(6):983-93. PubMed ID: 24577510
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas.
Schneider C; Setty M; Holmes AB; Maute RL; Leslie CS; Mussolin L; Rosolen A; Dalla-Favera R; Basso K
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8185-90. PubMed ID: 24843176
[TBL] [Abstract][Full Text] [Related]
15. Decitabine represses translocated MYC oncogene in Burkitt lymphoma.
Guan H; Xie L; Klapproth K; Weitzer CD; Wirth T; Ushmorov A
J Pathol; 2013 Apr; 229(5):775-83. PubMed ID: 23341364
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy.
Zhang MY; Calin GA; Yuen KS; Jin DY; Chim CS
Clin Epigenetics; 2020 Oct; 12(1):150. PubMed ID: 33076962
[TBL] [Abstract][Full Text] [Related]
17. Integrative microRNA and mRNA deep-sequencing expression profiling in endemic Burkitt lymphoma.
Oduor CI; Kaymaz Y; Chelimo K; Otieno JA; Ong'echa JM; Moormann AM; Bailey JA
BMC Cancer; 2017 Nov; 17(1):761. PubMed ID: 29132323
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells.
Sampson VB; Rong NH; Han J; Yang Q; Aris V; Soteropoulos P; Petrelli NJ; Dunn SP; Krueger LJ
Cancer Res; 2007 Oct; 67(20):9762-70. PubMed ID: 17942906
[TBL] [Abstract][Full Text] [Related]
19. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic regulation of CD44 in Hodgkin and non-Hodgkin lymphoma.
Eberth S; Schneider B; Rosenwald A; Hartmann EM; Romani J; Zaborski M; Siebert R; Drexler HG; Quentmeier H
BMC Cancer; 2010 Sep; 10():517. PubMed ID: 20920234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
